Shares of Calithera Biosciences Inc (NASDAQ:CALA) ended Monday session in red amid volatile trading. The shares closed down -0.05 points or -1.67% at $2.95 with 88,902.00 shares getting traded. Post opening the session at $3.00, the shares hit an intraday low of $2.95 and an intraday high of $3.10 and the price vacillated in this range throughout the day. The company has a market cap of $57.49 million and the numbers of outstanding shares have been calculated to be 19.49 million shares.
Calithera Biosciences Inc (CALA) announced that the first patient has been dosed in a Phase I clinical trial assessing the safety and efficacy of CB-1158, a first-in-class arginase inhibitor for the treatment of advanced solid tumors. Arginase is an enzyme in myeloid-derived suppressor cells (MDSCs), which prevents T-cell and natural killer (NK) cell activation in tumors.
“Arginase, when released by MDSCs, plays an important role in the inhibition of T-cell and NK-cell activation and proliferation, preventing immune-mediated anti-tumor activity. For example, in many solid tumors, including lung, colorectal, esophageal, bladder, head and neck, and kidney cancer, arginase-expressing MDSCs accumulate, establishing an immunosuppressive microenvironment by blocking the ability of T-cells and NK-cells to kill cancer cells. We believe that inhibitors of arginase can promote an anti-tumor immune response and augment the activity of checkpoint inhibitors,” said Susan M. Molineaux, Ph.D., founder, Chief Executive Officer and President of Calithera Biosciences. “We look forward to reporting initial clinical results with this compound in 2017.”
Shares of Ocera Therapeutics Inc (NASDAQ:OCRX) ended Monday session in green amid volatile trading. The shares closed up +0.15 points or 6.12% at $2.60 with 86,244.00 shares getting traded. Post opening the session at $2.50, the shares hit an intraday low of $2.50 and an intraday high of $2.60 and the price vacillated in this range throughout the day. The company has a market cap of $56.81 million and the numbers of outstanding shares have been calculated to be 21.85 million shares.
Ocera Therapeutics Inc (OCRX) announced completion of enrollment in STOP-ALF, a Phase 2a clinical trial to evaluate the Safety and Tolerability of Ornithine Phenylacetate in patients with Acute Liver Failure. The study was conducted by the Acute Liver Failure Study Group, an NIH-sponsored network of university tertiary care liver transplant sites, with support and supply of study medication from Ocera.
“We are excited to announce the completion of STOP-ALF and to report there were no serious safety issues attributable to study medication observed at any dose level,” said William M. Lee, M.D., principal investigator of the study. “We are currently examining additional safety and tolerability parameters, and pharmacokinetic findings for OCR-002 in these acutely ill patients. A late-breaker abstract of top-line findings has been submitted to the American Association for the Study of Liver Diseases (AASLD) for presentation at “The Liver Meeting®” being held in mid-November.